- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02309684
Bio-ConneKt Wound Dressing for Treatment of Chronic Leg Wounds: A Pilot Study
December 4, 2014 updated by: MLM Biologics Inc.,
The Clinical & Economic Evaluation of Bio-ConneKt® Wound Dressing in Treating Chronic Foot Ulcers (Diabetic and/or Venous Ulcers).
The purpose of this study is to assess the performance of the bio-ConneKt™ wound dressing and compare its performance with the standard of care at NFRMC Wound Therapy Services, for the treatment of chronic foot/leg ulcers (DFU/VLU) in a prospective single center open one-arm clinical study.
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Elmer Croushore, MD
- Phone Number: 352-538-3180
Study Contact Backup
- Name: Chandra Nataraj, PhD
- Phone Number: 352-514-4269
- Email: cnataraj@mlmbiologics.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
A total of 20 patients with DFU (n=10) and VLU (n=10) will be considered in this study if they sign the informed consent, and meet all inclusion criteria and none of the exclusion criteria.
Description
Inclusion Criteria:
- A full thickness diabetic foot ulcer with a viable wound bed free of necrotic material (grade 1 on Wagner scale) or a venous leg ulcer confirmed with duplex ultrasound
- The ulcer has been diagnosed/present for greater than 4 weeks duration.
- Three or fewer ulcers separated by > 3.0 cm distance
- Post-debridement, the ulcer size must be > 5 sq cm
Ankle / brachial index is between 0.7 to 1.2 and or one of the following must be present:
- transcutaneous partial pressure oxygen (TcPO2) > 30 mmHg at the ankle
- toe pressure of >40mm Hg or a Doppler waveform consistent with adequate flow in the foot (biphasic or triphasic)
- At least 18 years old
- Able and willing to read and sign a voluntary written informed consent
- Able and willing to attend scheduled follow-up visits and study related exams
Exclusion Criteria:
- Greater than 30% reduction in wound size (DFU) or 20% reduction in VLU during first week of observation by the investigator
- Ulcer with exposed tendon or bone
- Gross clinical infection at the study ulcer site including cellulitis and osteomyelitis
- Ulcer of a non-diabetic/non-venous pathophysiology (e.g., rheumatoid, radiation-related, and vasculitis related ulcers)
- Known severe anemia
- Known serum albumin < 2.5
- Renal failure requiring dialysis
- Rheumatoid arthritis (and other collagen vascular disease), vasculitis, sickle cell disease, HIV
- Severe liver disease as defined by the treating physician or patient's primary care physician
- Malignancy at or near the ulcer site
- Any condition judged by the investigator that would cause the study to be detrimental to the patient
- Presence of a hematology, clinical, chemistry or other test obtained within 7 days of screening that is outside the normal range for the laboratory and is determined to be clinically significant by the investigator
- Received another investigational device or drug within 30 days of Day 0.
- Radiation therapy, chemotherapy or immunosuppressive therapy within 30 days of enrollment
- Received another allograft, autograft or xenograft within 30 days of the Day 0/
- Known allergy to equine derived tissue
- Alcohol or drug abuse, defined as current medical treatment for substance abuse
- Pregnant or nursing women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Study Population
Study population are subjects at least 18 years old and of any ethnic background with a full thickness diabetic foot ulcer or venous leg ulcer, where the ulcer has been diagnosed/present for greater than 4 weeks duration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to complete wound closure
Time Frame: Weekly assessment up to 12 weeks
|
Time to complete wound closure and percent wounds healed at 12 weeks
|
Weekly assessment up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Wound Closure
Time Frame: 4, 6, 12 & 24 weeks
|
Mean and median wound size changes at 4, 6, 12 & 24 weeks, along with ulcer recurrence and/or device related adverse events.
|
4, 6, 12 & 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Elmer Croushore, MD, NFRMC Wound Therapy Services
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2015
Primary Completion (Anticipated)
June 1, 2015
Study Completion (Anticipated)
January 1, 2016
Study Registration Dates
First Submitted
December 3, 2014
First Submitted That Met QC Criteria
December 4, 2014
First Posted (Estimate)
December 5, 2014
Study Record Updates
Last Update Posted (Estimate)
December 5, 2014
Last Update Submitted That Met QC Criteria
December 4, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MLM1301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Ulcer
-
Zagazig UniversityCompletedUlcer Foot | Chronic Skin Ulcer | Non-Healing Ulcer of SkinEgypt
-
Groupe Hospitalier Paris Saint JosephCompletedUlcer, Leg | Ulcer AlgicFrance
-
Paul EdwardsCompletedDecubitis UlcerUnited States
-
University of ArkansasWithdrawnPressure Ulcer | Decubitus UlcerUnited States
-
Istituto Ortopedico RizzoliCompleted
-
University of KansasNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
University of California, IrvineBeckman Laser Institute University of California IrvineWithdrawn
-
Consorci Sanitari de l'Alt Penedès i GarrafNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedMARTORELL'S ULCER | Hypertensive Leg Ulcer | Necrotic AngiodermatitisFrance
-
Cairo UniversityCompleted